Neurology. Clinical practice最新文献

{"title":"Randomized Trial of Telegenetic Counseling for Gene Testing in Huntington Disease.","authors":"Deborah A Hall, Marc Rosenbaum, Jacob Hawkins, Bichun Ouyang, Christa Cooper, Neepa Patel","doi":"10.1212/CPJ.0000000000200394","DOIUrl":"https://doi.org/10.1212/CPJ.0000000000200394","url":null,"abstract":"<p><strong>Background and objectives: </strong>The purpose of the study was to determine the feasibility and patient satisfaction of telegenetic counseling, or counseling done by video, for Huntington disease (HD). Background: Genetic counseling is necessary for presymptomatic or symptomatic HD genetic testing, but the lack of access to counseling because of geography or expense is a critical gap for many patients. The hypothesis of this study was that there would be no difference in patient satisfaction between telegenetic counseling (tele-GC) or in-person counseling (in-person GC) for HD testing.</p><p><strong>Methods: </strong>This was a prospective, randomized, unblinded study of either tele-GC or in-person GC for HD gene testing. Participants had standardized genetic counseling in the clinic or through a Health Insurance Portability and Accountability Act (HIPAA) appropriate telemedicine platform first and then crossed over. A study coordinator interviewed the participant using a telehealth survey after each encounter.</p><p><strong>Results: </strong>A total of 19 in-person GC and 15 tele-GC participants were included: 68% women, 41 ± 15 years, 80% White, 10% Hispanic, and +CAG repeat length = 45 ± 4.4 (n = 15) (<i>p</i> > 0.1). All participants were satisfied with their initial counseling experience when asked to rate on a scale of 1-10 (median 10/10, <i>p</i> = 0.94). The majority of symptomatic HD participants (5/7) preferred in-person GC. The main advantage of tele-GC was reduction in travel time for both in-person GC first (n = 16) and tele-GC first (n = 11) participants. Technical challenges were encountered in many of the participants. Visually seeing the genetic counselor improved understanding for in-person GC (n = 10) and tele-GC (n = 8) participants. Participants felt they were able to pick up on emotional cues (n = 33) and felt comfortable asking questions (n = 34) using the tele-GC format.</p><p><strong>Discussion: </strong>Telegenetic counseling is a feasible option for HD gene testing, if patients are able to overcome technical issues. Having a video visit with both audio and video components, rather than an audio-only phone call, should be considered when using telegenetic counseling for HD. Finally, in-person counseling may be preferred to increase understanding of the genetic counseling materials in patients, especially in motor manifest HD.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 1","pages":"e200394"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Cavum Septum Pellucidum in Former American Football Players: Findings From the DIAGNOSE CTE Research Project.","authors":"","doi":"10.1212/CPJ.0000000000200414","DOIUrl":"https://doi.org/10.1212/CPJ.0000000000200414","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1212/CPJ.0000000000200324.].</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 1","pages":"e200414"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11547830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review of Sleep Disturbance in Idiopathic Intracranial Hypertension.","authors":"Sabrina Kentis, Jacob S Shaw, Lisa N Richey, Lisa Young, Natalia Kosyakova, Barry R Bryant, Aaron I Esagoff, Luis F Buenaver, Rachel Marie E Salas, Matthew E Peters","doi":"10.1212/CPJ.0000000000200372","DOIUrl":"https://doi.org/10.1212/CPJ.0000000000200372","url":null,"abstract":"<p><strong>Purpose of review: </strong>Sleep disturbances, particularly obstructive sleep apnea (OSA), may have a significant impact on the outcomes of patients with idiopathic intracranial hypertension (IIH). We conducted a PRISMA-compliant systematic literature review to study sleep disturbance in adult patients with IIH.</p><p><strong>Recent findings: </strong>The current literature on the relationship between IIH and sleep is quite limited. Research has found that sleep disturbances are associated with lower quality of life and may worsen several symptoms associated with IIH, such as headache, cognitive deficits, and neuropsychiatric issues.</p><p><strong>Summary: </strong>OSA was more prevalent in patients with IIH than in healthy controls. Several studies found that OSA was associated with worse IIH symptoms and treatment of OSA helped improve these parameters. Limitations included available literature and heterogeneity in sleep metrics and OSA diagnostic criteria between studies. Overall, further study of sleep disturbances in patients with IIH may encourage earlier screening, improved treatment options, and long-term improvements in quality of life.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 1","pages":"e200372"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142470859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing Prodrome (Premonitory Phase) in Migraine: Results From the PRODROME Trial Screening Period.","authors":"Todd J Schwedt, Richard B Lipton, Peter J Goadsby, Chia-Chun Chiang, Brad C Klein, Cory Hussar, Chengcheng Liu, Sung Yun Yu, Michelle Finnegan, Joel M Trugman","doi":"10.1212/CPJ.0000000000200359","DOIUrl":"https://doi.org/10.1212/CPJ.0000000000200359","url":null,"abstract":"<p><strong>Background and objective: </strong>Limited data are available describing the frequency, severity, and consistency of prodromal symptoms followed by headache. This analysis of the PRODROME trial screening period characterized prodromal symptoms in people with migraine, including the most common symptoms and their severity, and the frequency and consistency with which prodromal symptoms were followed by headache.</p><p><strong>Methods: </strong>PRODROME was a multicenter, randomized, double-blind, placebo-controlled, crossover trial conducted in the United States that enrolled adults with 2-8 migraine attacks per month who stated they could identify prodromal symptoms that were reliably followed by a headache. The trial included a 60-day screening period designed to test the predictive validity of \"qualifying prodrome events\" before the onset of headache. Participants used an eDiary to report qualifying prodrome events, defined as prodromal symptoms whereby the participant was confident a headache would follow within 1-6 hours. This analysis evaluated common prodromal symptoms and their severity, time from prodrome onset to headache onset, and the percentage of participants who identified prodromal symptoms that were followed by a headache ≥75% of the time over the 60-day screening period.</p><p><strong>Results: </strong>A total of 920 participants entered eDiary data, with a mean of 5.2 qualifying prodrome events during the 60-day screening period. A total of 4,802 qualifying prodrome events were recorded. The most common prodromal symptoms identified were sensitivity to light (57.2%; 2,748/4,802), fatigue (50.1%; 2,408/4,802), neck pain (41.9%; 2,013/4,802), sensitivity to sound (33.9%; 1,630/4,802), either difficulty thinking or concentrating (30.0%; 1,442/4,802), and dizziness (27.8%; 1,333/4,802). Of all qualifying prodrome events reported, 81.5% (3,913/4,802) were followed by headache of any intensity within 1-6 hours. For each participant, a mean of 84.4% of their qualifying prodrome events were followed by a headache within 1-6 hours, with 76.9% of participants identifying qualifying prodrome events that were followed by headache within 1-6 hours ≥75% of the time.</p><p><strong>Discussion: </strong>Participants were able to identify migraine attacks in which prodromal symptoms were reliably followed by a headache within 1-6 hours. These findings suggest the potential for initiating treatment during the prodrome to prevent headache.</p><p><strong>Trial registration information: </strong>ClinicalTrials.gov NCT04492020. Submitted: July 27, 2020; First patient enrolled: August 21, 2020. clinicaltrials.gov/study/NCT04492020.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 1","pages":"e200359"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142470864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Missing Full Disclosures.","authors":"","doi":"10.1212/CPJ.0000000000200416","DOIUrl":"https://doi.org/10.1212/CPJ.0000000000200416","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1212/cpj.0000000000200192.][This corrects the article DOI: 10.1212/cpj.0000000000200200.][This corrects the article DOI: 10.1212/cpj.0000000000200184.][This corrects the article DOI: 10.1212/cpj.0000000000200201.][This corrects the article DOI: 10.1212/cpj.0000000000200206.][This corrects the article DOI: 10.1212/cpj.0000000000200198.][This corrects the article DOI: 10.1212/cpj.0000000000200195.][This corrects the article DOI: 10.1212/cpj.0000000000200204.][This corrects the article DOI: 10.1212/cpj.0000000000200213.][This corrects the article DOI: 10.1212/cpj.0000000000200203.][This corrects the article DOI: 10.1212/cpj.0000000000200207.][This corrects the article DOI: 10.1212/cpj.0000000000200194.].</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 1","pages":"e200416"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11606146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional Connectivity Relationships to Longitudinal Motor Outcomes Differ in Very Preterm Children With and Without Brain Injury.","authors":"Peppar E P Cyr, Rachel E Lean, Jeanette K Kenley, Sydney Kaplan, Dominique Meyer, Jeffrey J Neil, Dimitrios Alexopoulos, Rebecca G Brady, Joshua S Shimony, Thomas L Rodebaugh, Cynthia E Rogers, Christopher D Smyser","doi":"10.1212/CPJ.0000000000200397","DOIUrl":"10.1212/CPJ.0000000000200397","url":null,"abstract":"<p><strong>Background and objectives: </strong>Children born very preterm (VPT) have high rates of motor disability, but mechanisms for early identification remain limited, especially for children who fall behind in early childhood. This study examines the relationship between functional connectivity (FC) measured at term-equivalent age and motor outcomes at 2 and 5 years.</p><p><strong>Methods: </strong>In this longitudinal observational cohort study, VPT children (gestational age 30 weeks and younger) with and without high-grade brain injury underwent FC MRI at term-equivalent age. Motor development was assessed using the Bayley Scales of Infant Development, Third Edition, at corrected age 2 years and Movement Assessment Battery for Children, Second Edition, at age 5 years. Logistic and negative binomial/Poisson regression models examined relationships between FC measures and 5-year task scores, with and without 2-year scores as covariates. Infants were categorized as \"injured\" or \"uninjured\" based on structural MRI findings at term-equivalent age.</p><p><strong>Results: </strong>In the injured group (n = 34), each 1 SD decrease in neonatal left-right motor cortex FC was related to approximately 4× increased odds of being unable to complete a fine motor task at age 5 (log odds = -1.34, <i>p</i> < 0.05). In the uninjured group (n = 41), stronger basal ganglia-motor cortex FC was related to poorer fine motor scores (Est = -0.40, <i>p</i> < 0.05) and stronger cerebellum-motor cortex FC was related to poorer balance and fine motor scores (Est = -0.05 to -0.23, <i>p</i> < 0.05), with balance persisting with adjustment for 2-year scores.</p><p><strong>Discussion: </strong>In VPT children with brain injury, interhemispheric motor cortex FC was related to motor deficits at 5-year assessment, similar to previous findings at 2 years. In uninjured children, FC-measured disruption of the motor system during the neonatal period was associated with motor planning/coordination difficulties that were not apparent on 2-year assessment but emerged at 5 years, suggesting that the neural basis of these deficits was established very early in life. Subsequently, 2-year follow-up may not be sufficient to detect milder motor deficits in VPT children, and they should be monitored for motor difficulties throughout the preschool years. For all VPT children, FC at term-equivalent age has the potential to improve our ability to predict disability before it presents behaviorally.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 1","pages":"e200397"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142504827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Dysphagia in Epilepsy Patients: The Silent Enemy.","authors":"","doi":"10.1212/CPJ.0000000000200423","DOIUrl":"https://doi.org/10.1212/CPJ.0000000000200423","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1212/CPJ.0000000000200362.].</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 1","pages":"e200423"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11547828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in Utilization of Outpatient Telemedicine for Neurologic Care.","authors":"Marisa Patryce McGinley, Tucker Harvey, Daniel Ontaneda, Allison L Weathers, Bryan R Cobb, Anisha Patel","doi":"10.1212/CPJ.0000000000200407","DOIUrl":"10.1212/CPJ.0000000000200407","url":null,"abstract":"<p><strong>Background and objectives: </strong>To characterize outpatient telemedicine utilization for neurologic conditions and identify potential disparities.</p><p><strong>Methods: </strong>All outpatient visits conducted by neurology clinicians at an academic medical health care system for patients aged 18 years or older from January 2019 to July 2022 were included. All telemedicine visits were synchronous audio-visual. Patients completing in-person visits alone were compared with patients completing telemedicine visits. Utilization of telemedicine was compared across 3 time frames: prepandemic (before March 2020), early-pandemic (March-June 2020), and late-pandemic (July 2020-July 2022). Generalized linear mixed-effects models were used to evaluate whether the odds of a visit being telemedicine vs in-person differed based on the time frame and to predict likelihood of telemedicine vs in-person visit in late pandemic time frame.</p><p><strong>Results: </strong>In total, 242,273 patients (mean age 55.9 years, 58.2% female, 81.9% White, 12.5% Black, 3.4% Hispanic, 39.2% Medicare) completed 752,174 visits during the study time frame. There was a significant difference in telemedicine utilization between the time frames, with the highest utilization being in the early pandemic (<i>p</i> 0.01). In the late pandemic time frame, odds of a telemedicine visit were significantly lower for individuals who were older (odds ratio [OR] 0.97), Black (OR 0.84), Hispanic (OR 0.70), a higher Area Deprivation Index (20%-40%: OR 0.85, 40%-60%: OR 0.80, 60%-80%: OR 0.78, ≥80%: OR 0.65), with nonprivate insurance (Medicaid OR 0.78; Medicare OR 0.84; self-pay OR 0.60), and non-English preferred language (OR 0.61) (<i>p</i> < 0.01 for all). Odds of a telemedicine visit were significantly higher for individuals who were female (OR 1.25) and lived outside of the greater Cleveland area (other Ohio OR 2.33; out of state OR 3.32) (<i>p</i> < 0.01). Visits completed by rural patients did not differ significantly from metropolitan patients (OR 0.95, <i>p</i> = 0.09).</p><p><strong>Discussion: </strong>Disparities in telemedicine persist with lower use in individuals who were older, Black, Hispanic, non-English preferred language, and lower socioeconomic status. These disparities improved initially but were accentuated later in the pandemic. The equal utilization of telemedicine by rural and urban patients in this study suggests the potential of telemedicine to improve access disparities for rural patients. The implementation of equitable health care delivery will require a better understanding of barriers, preferences, and legislation needed to support equitable telemedicine access.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 1","pages":"e200407"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between LACE+ Index Risk Category and 90-Day Mortality After Stroke.","authors":"Adalia Jun-O'Connell, Brian Silver, Eliza Grigoriciuc, Akanksha Gulati, Kimiyoshi J Kobayashi, Nils Henninger","doi":"10.1212/CPJ.0000000000200363","DOIUrl":"https://doi.org/10.1212/CPJ.0000000000200363","url":null,"abstract":"<p><strong>Background and objectives: </strong>A higher LACE+ index risk category (defined as LACE+ score ≥78) typically calculated before hospital discharge has been associated with increased risk of unplanned 30-day hospital readmissions and early death after hospital discharge. However, its utility to predict poststroke mortality is unknown. Here, we examined whether the LACE+ index risk category assessed at both discharge (dLACE+) and admission (aLACE+) was associated with 90-day mortality after stroke.</p><p><strong>Methods: </strong>We retrospectively analyzed 2,729 consecutive patients who presented with ischemic or hemorrhagic strokes, included in an institutional stroke registry between January 2018 and December 2021. The primary outcome of interest was 90-day mortality after the index hospitalization. Patients were categorized as high-risk (≥78), medium-to-high-risk (59-77), and low-to-medium-risk (0-58) according to the LACE+ as automatically calculated at admission and discharge. Analyses were performed on the entire cohort, as well as stratified according to acute ischemic stroke and hemorrhagic stroke diagnosis.</p><p><strong>Results: </strong>Among patients who completed 90-day follow-up, the mortality rate was 24.3% (576/2368). In the Kaplan-Meier analysis, the high-risk aLACE+ group had the highest 90-day mortality rate as compared with low-to-medium-risk and medium-to-high-risk groups (<i>p</i> < 0.001). In a fully adjusted multivariable Cox-regression, the 90-day hazards of death were significantly greater among participants in a high-risk aLACE+ (aHR 1.7, 95% CI 1.080-2.742, <i>p</i> = 0.022) and medium-to-high-risk aLACE+ categories (aHR 1.4, 95% CI 1.141-1.778, <i>p</i> = 0.002) as compared with participants in the low-to-medium-risk aLACE+ category. Results were overall similar for dLACE+.</p><p><strong>Discussion: </strong>The LACE+ calculated at both admission and discharge admission identified patients with stroke at increased risk for 90-day mortality. Future studies are warranted to determine whether LACE+ score-based risk stratification can be used to devise early interventions to mitigate the risk for death.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 1","pages":"e200363"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142470863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments.","authors":"Jennifer Morganroth, Chafic Karam","doi":"10.1212/CPJ.0000000000200368","DOIUrl":"https://doi.org/10.1212/CPJ.0000000000200368","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this review is to give an update on myelin-associated glycoprotein (MAG) neuropathy.</p><p><strong>Recent findings: </strong>There are several recent developments in anti-MAG neuropathy, with the major one being the retrospective analysis of 50 clinical trials that showed that at least a 50% reduction in anti-MAG levels is associated with a therapeutic response. Other updates address antibody levels needed for a positive test, response, and exacerbations to therapy and the type of antibody more associated with malignancy.</p><p><strong>Implications for practice: </strong>Anti-MAG neuropathy is heterogeneous, and the natural history of the disease continues to be refined. Treatment options are being explored for refractory disease.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 1","pages":"e200368"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142470861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}